Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 4/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.54 |
| ▸ | CCNK | O75909 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CCND3 | P30281 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.53 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690427 | 0.87 | CCNA2 (0.67) | MAPK9MAPK10MAPK8CCNKCCNA2 | |
| SCHEMBL31251143 | 0.77 | EGFR (0.60) | BRD4ALKAXLNEK2EGFR | |
| SCHEMBL24993662 | 0.76 | MAPK9 (0.48) | MAPK9MAPK10MAPK8CCNKCCNA2 | |
| SCHEMBL32690365 | 0.76 | ALK (0.60) | MAPK9MAPK10MAPK8CCNKCCNA2 | |
| SCHEMBL32690420 | 0.75 | PTK2 (0.76) | MAPK9MAPK10MAPK8CCNKCCNA2 | |
| SCHEMBL12780114 | 0.75 | ZAP70 (0.67) | MAPK9MAPK10MAPK8CCNKCCNA2 | |
| SCHEMBL29904658 | 0.73 | CDK9 (0.59) | MAPK9MAPK10MAPK8CCNKCCNA2 | |
| SCHEMBL26906721 | 0.73 | CDK9 (0.59) | MAPK9MAPK10MAPK8CCNKCCNA2 | |
| SCHEMBL12780515 | 0.73 | ZAP70 (0.82) | MAPK9MAPK10MAPK8CCNKCCNA2 | |
| SCHEMBL12781687 | 0.73 | ZAP70 (0.64) | MAPK9MAPK10MAPK8CCNKCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | MAPK9 444/4885MAPK10 592/4885MAPK8 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.